OBJECTIVE: To estimate the prevalence of HIV drug resistance over time and identify risk factors for multiclass resistance. DESIGN: Prospective clinical cohort of HIV-infected patients at the University of North Carolina. METHODS: Among antiretroviral therapy (ART)-experienced patients in care 2000-2016, we estimated annual prevalences of cumulative resistance, defined as at least one major mutation by drug class. Clinical data and multiple imputation were used when genotypic data were missing, and mutations were carried forward in time. We estimated resistance odds ratios comparing characteristics of patients in care in 2016. RESULTS: A total of 3682 patients contributed 23 169 person-years. Prevalence of at least one major resistance mutation, irrespective of viral suppression, peaked in 2005 with 49% (95% confidence interval 46, 52) and decreased to 38% (35, 40) in 2016. Resistance to nucleoside reverse transcriptase inhibitors, protease inhibitors, and nonnucleoside reverse transcriptase inhibitors also peaked in 2005-2007 and decreased to 28 (26, 31), 14 (12, 16), and 27% (24, 29) in 2016, respectively. In 2016, prevalence of integrase strand transfer inhibitor (INSTI) resistance was 2% (1, 3) and triple-class resistance 10% (9, 12). Over the study period, cumulative resistance was frequent among patients with detectable viremia, but uncommon among patients initiating ART post-2007. Among 1553 patients in care in 2016, ART initiation at an older age, with an INSTI, and with higher CD4 cell counts were associated with resistance to fewer or no classes. CONCLUSION: Prevalence of resistance to older ART classes has decreased in the last 10 years in this clinical cohort, whereas INSTI resistance has increased but remained very low. Patients with viremia continue to have a high burden of resistance even if they initiated ART recently.
OBJECTIVE: To estimate the prevalence of HIV drug resistance over time and identify risk factors for multiclass resistance. DESIGN: Prospective clinical cohort of HIV-infectedpatients at the University of North Carolina. METHODS: Among antiretroviral therapy (ART)-experienced patients in care 2000-2016, we estimated annual prevalences of cumulative resistance, defined as at least one major mutation by drug class. Clinical data and multiple imputation were used when genotypic data were missing, and mutations were carried forward in time. We estimated resistance odds ratios comparing characteristics of patients in care in 2016. RESULTS: A total of 3682 patients contributed 23 169 person-years. Prevalence of at least one major resistance mutation, irrespective of viral suppression, peaked in 2005 with 49% (95% confidence interval 46, 52) and decreased to 38% (35, 40) in 2016. Resistance to nucleoside reverse transcriptase inhibitors, protease inhibitors, and nonnucleoside reverse transcriptase inhibitors also peaked in 2005-2007 and decreased to 28 (26, 31), 14 (12, 16), and 27% (24, 29) in 2016, respectively. In 2016, prevalence of integrase strand transfer inhibitor (INSTI) resistance was 2% (1, 3) and triple-class resistance 10% (9, 12). Over the study period, cumulative resistance was frequent among patients with detectable viremia, but uncommon among patients initiating ART post-2007. Among 1553 patients in care in 2016, ART initiation at an older age, with an INSTI, and with higher CD4 cell counts were associated with resistance to fewer or no classes. CONCLUSION: Prevalence of resistance to older ART classes has decreased in the last 10 years in this clinical cohort, whereas INSTI resistance has increased but remained very low. Patients with viremia continue to have a high burden of resistance even if they initiated ART recently.
Authors: Christine Katlama; Bonaventura Clotet; Anthony Mills; Benoit Trottier; Jean-Michel Molina; Beatriz Grinsztejn; William Towner; Richard Haubrich; Steven Nijs; Johan Vingerhoets; Brian Woodfall; James Witek Journal: Antivir Ther Date: 2010
Authors: Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Lijie Zhong; Kitty Yale; Kirsten White; Brian P Kearney; Javier Szwarcberg; Erin Quirk; Andrew K Cheng Journal: Lancet Date: 2012-06-30 Impact factor: 79.321
Authors: Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Alexandra U Scherrer; Viktor von Wyl; Wan-Lin Yang; Roger D Kouyos; Jürg Böni; Sabine Yerly; Thomas Klimkait; Vincent Aubert; Matthias Cavassini; Manuel Battegay; Hansjakob Furrer; Alexandra Calmy; Pietro Vernazza; Enos Bernasconi; Huldrych F Günthard; V Aubert; M Battegay; E Bernasconi; J Böni; D L Braun; H C Bucher; C Burton-Jeangros; A Calmy; M Cavassini; G Dollenmaier; M Egger; L Elzi; J Fehr; J Fellay; H Furrer; C A Fux; M Gorgievski; H Günthard; D Haerry; B Hasse; H H Hirsch; M Hoffmann; I Hösli; C Kahlert; L Kaiser; O Keiser; T Klimkait; R Kouyos; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; C Marzolini; K Metzner; N Müller; D Nadal; D Nicca; G Pantaleo; A Rauch; S Regenass; C Rudin; F Schöni-Affolter; P Schmid; R Speck; M Stöckle; P Tarr; A Trkola; P Vernazza; R Weber; S Yerly Journal: Clin Infect Dis Date: 2016-03-08 Impact factor: 9.079
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: C A Kleeberger; J P Phair; S A Strathdee; R Detels; L Kingsley; L P Jacobson Journal: J Acquir Immune Defic Syndr Date: 2001-01-01 Impact factor: 3.731
Authors: Viktor von Wyl; Sabine Yerly; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Hansjakob Furrer; Bernard Hirschel; Pietro L Vernazza; Patrick Francioli; Sebastian Bonhoeffer; Bruno Ledergerber; Huldrych F Günthard Journal: Clin Infect Dis Date: 2009-04-01 Impact factor: 9.079
Authors: Joseph J Eron; David A Cooper; Roy T Steigbigel; Bonaventura Clotet; Jose M Gatell; Princy N Kumar; Jurgen K Rockstroh; Mauro Schechter; Martin Markowitz; Patrick Yeni; Mona R Loutfy; Adriano Lazzarin; Jeffrey L Lennox; Kim M Strohmaier; Hong Wan; Richard J O Barnard; Bach-Yen T Nguyen; Hedy Teppler Journal: Lancet Infect Dis Date: 2013-05-07 Impact factor: 25.071
Authors: Thibaut Davy-Mendez; Sonia Napravnik; Oksana Zakharova; David A Wohl; Claire E Farel; Joseph J Eron Journal: AIDS Date: 2019-06-01 Impact factor: 4.177
Authors: William A Werbel; Diane M Brown; Oyinkansola T Kusemiju; Brianna L Doby; Shanti M Seaman; Andrew D Redd; Yolanda Eby; Reinaldo E Fernandez; Niraj M Desai; Jernelle Miller; Gilad A Bismut; Charles S Kirby; Haley A Schmidt; William A Clarke; Michael Seisa; Christos J Petropoulos; Thomas C Quinn; Sander S Florman; Shirish Huprikar; Meenakshi M Rana; Rachel J Friedman-Moraco; Aneesh K Mehta; Peter G Stock; Jennifer C Price; Valentina Stosor; Shikha G Mehta; Alexander J Gilbert; Nahel Elias; Michele I Morris; Sapna A Mehta; Catherine B Small; Ghady Haidar; Maricar Malinis; Jennifer S Husson; Marcus R Pereira; Gaurav Gupta; Jonathan Hand; Varvara A Kirchner; Avinash Agarwal; Saima Aslam; Emily A Blumberg; Cameron R Wolfe; Kevin Myer; R Patrick Wood; Nikole Neidlinger; Sara Strell; Marion Shuck; Harry Wilkins; Matthew Wadsworth; Jennifer D Motter; Jonah Odim; Dorry L Segev; Christine M Durand; Aaron A R Tobian Journal: Clin Infect Dis Date: 2022-06-10 Impact factor: 20.999
Authors: Kimia Kamelian; Katherine J Lepik; William Chau; Benita Yip; Wendy W Zhang; Viviane Dias Lima; Marjorie A Robbins; Conan Woods; Andrea Olmstead; Jeffrey B Joy; Rolando Barrios; P Richard Harrigan Journal: Open Forum Infect Dis Date: 2019-02-12 Impact factor: 3.835
Authors: Soo-Yon Rhee; Dana Clutter; C Bradley Hare; Christophe T Tchakoute; Kristin Sainani; W Jeffrey Fessel; Leo Hurley; Sally Slome; Benjamin A Pinsky; Michael J Silverberg; Robert W Shafer Journal: Open Forum Infect Dis Date: 2020-08-06 Impact factor: 3.835
Authors: Joseph C Gathe; Robin L Hardwicke; Fernando Garcia; Steven Weinheimer; Stanley T Lewis; Robert Brandon Cash Journal: J Acquir Immune Defic Syndr Date: 2021-04-01 Impact factor: 3.771
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632
Authors: Madita Schlösser; Vladimir V Kartashev; Visa H Mikkola; Andrey Shemshura; Sergey Saukhat; Dmitriy Kolpakov; Alexandr Suladze; Tatiana Tverdokhlebova; Katharina Hutt; Eva Heger; Elena Knops; Michael Böhm; Veronica Di Cristanziano; Rolf Kaiser; Anders Sönnerborg; Maurizio Zazzi; Marina Bobkova; Saleta Sierra Journal: Viruses Date: 2020-04-22 Impact factor: 5.048
Authors: Ana R Pascom; Rosana Egg Pinho; Fernanda Rick; Nazle Mc Veras; Filipe de Barros Perini; Mariana V Meireles; Gerson F Pereira; Adele S Benzaken; Vivian I Avelino-Silva Journal: J Int AIDS Soc Date: 2019-11 Impact factor: 5.396